Invuity (NASDAQ:IVTY) released its earnings results on Tuesday. The medical instruments supplier reported ($0.43) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.50) by $0.07, Bloomberg Earnings reports. The company had revenue of $11.23 million for the quarter, compared to the consensus estimate of $11.84 million. Invuity had a negative return on equity of 212.38% and a negative net margin of 111.43%.
Invuity (NASDAQ IVTY) traded down $0.55 during midday trading on Wednesday, reaching $3.95. The company had a trading volume of 479,800 shares, compared to its average volume of 291,645. The stock has a market capitalization of $77.13, a P/E ratio of -1.60 and a beta of -0.50. The company has a quick ratio of 2.47, a current ratio of 2.90 and a debt-to-equity ratio of 5.39. Invuity has a 12 month low of $3.75 and a 12 month high of $9.70.
IVTY has been the topic of several analyst reports. Piper Jaffray Companies reiterated a “buy” rating and set a $12.00 target price on shares of Invuity in a research report on Friday, November 10th. Zacks Investment Research downgraded Invuity from a “hold” rating to a “sell” rating in a research report on Wednesday, January 10th. Finally, Northland Securities reiterated a “buy” rating and set a $6.00 target price on shares of Invuity in a research report on Wednesday. One analyst has rated the stock with a sell rating, one has assigned a hold rating and four have issued a buy rating to the company. The company currently has a consensus rating of “Buy” and an average target price of $8.50.
Invuity, Inc, a medical technology company, develops various surgical devices to address various surgical procedures in the United States. The company integrates its intelligent photonics technology platform into its single-use and reusable advanced surgical devices to address various critical intracavity illumination and visualization challenges.
Receive News & Ratings for Invuity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Invuity and related companies with MarketBeat.com's FREE daily email newsletter.